Medical technology

BIOTRONIK's Implantable Cardiac Monitor Receives Prestigious Industry Award

Retrieved on: 
Wednesday, July 28, 2021
Cardiac electrophysiology, Branches of biology, Biomedical engineering, Prosthetics, Medical technology, Medicine, Cardiac monitoring, Medical monitoring, Heart, Implant

"By allowing patients' recorded cardiac rhythm disturbance to be automatically and wirelessly transmitted to physicians, the solution enables 24-hour monitoring from anywhere.

Key Points: 
  • "By allowing patients' recorded cardiac rhythm disturbance to be automatically and wirelessly transmitted to physicians, the solution enables 24-hour monitoring from anywhere.
  • "Such efficacy is useful, especially during the COVID-19 pandemic, as physicians can continually monitor patients for warning signs without hospital visits."
  • Miniaturized implantable cardiac monitor with a long sensing vector (BIOMONITOR III): Insertion procedure assessment, sensing performance, and home monitoring transmission success.
  • Hayes, D, Reddy R and Whittington, H. Correlation of Vital Signs Facilitates Illness Screening in an Implantable Cardiac Monitor.

Synchron Receives Green Light From FDA to Begin Breakthrough Trial of Implantable Brain Computer Interface in US

Retrieved on: 
Wednesday, July 28, 2021
FDA, Health, Technology, Other Technology, Other Health, Clinical trials, Branches of biology, Medical technology, Biology, Biomedical engineering, Prosthetics, Thomas Oxley, Neuroprosthetics, Brain–computer interfacing, Implant, THE STENTRODETM, SYNCHRON, INC.

Outcomes will include the use of the brain data to control digital devices and achieve improvements in functional independence.

Key Points: 
  • Outcomes will include the use of the brain data to control digital devices and achieve improvements in functional independence.
  • The FDA granted Breakthrough Device designation to Synchron in August 2020 .
  • We are thrilled to finally be launching a U.S. clinical trial this year, said Synchron CEO Thomas Oxley, MD, PhD.
  • Other implantable BCI approaches involve drilling into the skull and placing needle electrodes directly into the brain tissue, which can result in long term brain inflammation.

DGAP-News: Vitruvia Medical AG: Successful certification for the reprocessing of 'critical C' devices - Vitruvia Medical now also providing circular systems for highest risk-level medical devices

Retrieved on: 
Wednesday, July 28, 2021
Medicine, Clinical medicine, Computer-assisted surgery, Medical technology, Telemedicine, Diagnostic gastroenterology, Endoscopy, ISO 13485, Robot-assisted surgery, Robot, Surgery

Schnebeck, July 28, 2021 Vitruvia Medical, which specializes in circular systems for highly complex medical products, particularly robot-assisted surgery, now also holds

Key Points: 
  • Schnebeck, July 28, 2021 Vitruvia Medical, which specializes in circular systems for highly complex medical products, particularly robot-assisted surgery, now also holds
    DIN EN ISO 13485:2016 (KRINKO) certification.
  • This means that Vitruvia Medical is now certified to reprocess all surgical instruments, including those classed at the highest "critical C" risk level.
  • These include flexible endoscopes as well as all instruments and optics for robot-assisted surgery which are authorized for reprocessing by the manufacturer.
  • With this sustainable concept, hospitals save both investment and operating costs when using robot-assisted surgical systems and also avoid the potential underuse of their own circular systems.

AngelMed Announces First Commercial Implantation of Real-Time Heart Attack Warning System

Retrieved on: 
Tuesday, July 27, 2021
Medicine, Medical technology, Branches of biology, Medical emergencies, Biomedical engineering, Prosthetics, Acute coronary syndrome, Syndromes affecting the heart, Implant

Indicated for acute coronary syndrome (ACS) events, including silent heart attacks, The Guardian Systemis the first implantable cardiac detection monitor and patient-warning system.

Key Points: 
  • Indicated for acute coronary syndrome (ACS) events, including silent heart attacks, The Guardian Systemis the first implantable cardiac detection monitor and patient-warning system.
  • Dr. Kaplan is a pioneer of new cardiac technologies and has played a significant role in The Guardian's commercialization.
  • "The first commercial implant of The Guardian marks a pivotal advancement in cardiac care.
  • The device detects impending ACS events, including silent heart attacks, and leads to earlier patient treatment," said Dr. Andrew Kaplan.

U.S. Retractable Needle Safety Syringes Market Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 27, 2021
Medical Supplies, Health, Medical equipment, Medical technology, Health sciences, Medicine, Drug paraphernalia, Safety syringe, Syringe, Needlestick injury, Needle, Needle remover

The "U.S. Retractable Needle Safety Syringes Market, by Product Type, by End User, and by Distribution Channel - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "U.S. Retractable Needle Safety Syringes Market, by Product Type, by End User, and by Distribution Channel - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.
  • A needle is a solid and slender instrument, which is pointed at the end and is designed for puncturing of tissues.
  • Safety needles have a safety mechanism built into the needles to protect healthcare workers and others from accidental needlestick injuries.
  • Rising prevalence of gynecologic cancer and spine disorders, government initiatives for blood collection and favorable reimbursement for pen needles are some of the major factors responsible for the growth of the U.S. retractable needle safety syringes market.

MicroPort® Cardiac Rhythm Management Business Announces US$150 Million Series C Investment

Retrieved on: 
Tuesday, July 27, 2021
Medical technology, Cardiac electrophysiology, Branches of biology, Life sciences, Medical devices, Neuroprosthetics, Microport, Biomedical engineering, Embedded systems, Microport, Artificial cardiac pacemaker, Implantable cardioverter-defibrillator

SHANGHAI, July 27, 2021 /PRNewswire/ -- MicroPort Scientific Corporation ("MicroPort") announced that MicroPort Cardiac Rhythm Management Limited ("MicroPort CRM"), which is MicroPort's subsidiary focused on developing and commercializing implantable pacemaker and defibrillator devices and related technologies to manage cardiac rhythm disorders, has entered into definitive agreements in connection with its Series C financing with total investment proceeds of US$150 million.

Key Points: 
  • SHANGHAI, July 27, 2021 /PRNewswire/ -- MicroPort Scientific Corporation ("MicroPort") announced that MicroPort Cardiac Rhythm Management Limited ("MicroPort CRM"), which is MicroPort's subsidiary focused on developing and commercializing implantable pacemaker and defibrillator devices and related technologies to manage cardiac rhythm disorders, has entered into definitive agreements in connection with its Series C financing with total investment proceeds of US$150 million.
  • Hillhouse Capital Group and MicroPort will co-lead the Series C investment and will invest US$20 million and US$47 million, respectively.
  • After the completion of this transaction, MicroPort will continue to be the majority shareholder of MicroPort CRM.
  • Through its long-standing expertise in CRM, MicroPort CRM develops, manufactures and markets around the world cardiac pacemakers, implantable cardiac defibrillators, cardiac resynchronization systems and ECG diagnostic solutions for the management of cardiac rhythm disorders and heart failure.

Medtronic TYRX™ Absorbable Antibacterial Envelope Is Effective at Reducing Infections in Cardiac Device Patients with Hematomas

Retrieved on: 
Monday, July 26, 2021
Medical technology, Medical devices, Prosthetics, Branches of biology, Medicine, Biomedical engineering, Implant, Tissue engineering, Neurostimulation

The analysis showed an 82% reduction in major CIED infections among patients with the TYRX Envelope who developed hematomas compared to patients in the control group who developed hematomas.

Key Points: 
  • The analysis showed an 82% reduction in major CIED infections among patients with the TYRX Envelope who developed hematomas compared to patients in the control group who developed hematomas.
  • The incidence of hematomas was 2.2% (151 patients) and was similar among control and envelope patients.
  • The TYRX Envelope is an absorbable, single-use device that holds a cardiac implantable electronic device or implanted neurostimulator.
  • Cost-Effectiveness Analyses of an Absorbable Antibacterial Envelope for Use in Patients at Increased Risk of Cardiac Implantable Electronic Device Infection in Germany, Italy, and England.

Novadiscovery appoints Grégoire Boutonnet as Chief Operating Officer

Retrieved on: 
Thursday, July 22, 2021
Articles, Health sciences, Clinical research, Health, Computational science, Medical technology, Contract research organizations, Drug discovery, In silico clinical trials, Blockchain, Clinical trial, ERT

Lyon, France 22 July 2021: Novadiscovery (NOVA), a leading health tech company using in silico clinical trials to predict drug efficacy and optimize clinical trial development, today announces the appointment of Grgoire Boutonnet as Chief Operating Officer, effective immediately.

Key Points: 
  • Lyon, France 22 July 2021: Novadiscovery (NOVA), a leading health tech company using in silico clinical trials to predict drug efficacy and optimize clinical trial development, today announces the appointment of Grgoire Boutonnet as Chief Operating Officer, effective immediately.
  • Grgoire then joinedtelecoms service provider Cirpack, following its acquisition of Andrexen, as Chief Marketing and Product Officer.
  • He most recently held the position of Chief Strategy Officer at Experty.io, a blockchain-based knowledge sharing platform.
  • Grgoire Boutonnet, Chief Operating Officer of NOVA, said: I am thrilled to be joining the NOVA team at this exciting period of growth as we launch the Jink platform towards wider adoption in the clinical trial development space.

Relay Announces Engagement with Canadian MedTech Leader, StarFish Medical, to provide Cybeats Integrated Security Platform for Connected Medical Devices

Retrieved on: 
Thursday, July 22, 2021
Technology, Science and technology, Articles, Medical technology, Cyberwarfare, Medical equipment, Ambient intelligence, Internet of things, Medical device, Computer security, ISO 13485

TORONTO, July 22, 2021 (GLOBE NEWSWIRE) -- Relay Medical Corp. (Relay or the Company) (CSE: RELA, OTCQB: RYMDF, Frankfurt: EIY2) announces an engagement to provide the Cybeats integrated cybersecurity platform to StarFish Product Engineering Inc. (StarFish Medical), the largest medical device design consultancy in Canada.

Key Points: 
  • TORONTO, July 22, 2021 (GLOBE NEWSWIRE) -- Relay Medical Corp. (Relay or the Company) (CSE: RELA, OTCQB: RYMDF, Frankfurt: EIY2) announces an engagement to provide the Cybeats integrated cybersecurity platform to StarFish Product Engineering Inc. (StarFish Medical), the largest medical device design consultancy in Canada.
  • Under the engagement, Relay will provide the Cybeats cybersecurity platform to StarFish Medical for high-valued connected medical devices.
  • StarFish Medical is Canada's leading medical device design, development and contract manufacturing company with ISO 13485 certified engineering and finished manufacturing services.
  • Cybeats Integrated Cybersecurity Platform has been designed for securing the internet of things (IoT) and other connected devices.

Medtronic Hugo™ Robotic-Assisted Surgery System Cornerstone of New Robotics Program in Latin America

Retrieved on: 
Tuesday, July 20, 2021
Computer-assisted surgery, Telemedicine, Health informatics, Medical technology, Health, Robot-assisted surgery, Medtronic, Surgery, Medicine

Touch Surgery Enterprise, a cloud-based surgical video capture option powered by artificial intelligence, allows surgeons to seamlessly record, analyze, and share Hugo system case footage.

Key Points: 
  • Touch Surgery Enterprise, a cloud-based surgical video capture option powered by artificial intelligence, allows surgeons to seamlessly record, analyze, and share Hugo system case footage.
  • "With Hugo RAS system, we are entering a new era of robotic-assisted surgery, improving how we deliver high quality healthcare to our patients."
  • In support of its commitment to expand access to quality care, Medtronic has opened a new Surgical Robotics Experience Center in Santiago.
  • This is the company's first in Latin America and 1 of 10 world-class facilities around the globe where clinicians can experience and train on the Hugo RAS system.